The most advanced WEE1 inhibitor in development, AZD1775 (adavosertib) [117], is currently being investigated in more than a dozen clinical trials targeting lung (NCT02513563), ovarian (NCT01164995, NCT02101775, and NCT03579316), renal (NCT03284385), pancreatic (NCT02101775), uterine (NCT03668340), bladder (NCT02546661), cervical (NCT03345784), hematopoietic (NCT04439227), and neural (NCT02095132 and NCT01849146) cancers. Here, WEE1 is linked to cancer.